Novo Nordisk has launched a subscription program for Wegovy, letting cash-paying patients buy 3-month, 6-month, or yearlong bundles for injections and oral formulations, the company said. The model is positioned as a more predictable way to pay for therapy akin to subscription services. The move arrives as the GLP-1 obesity market continues to expand with ongoing manufacturing scale-up and growing competition across branded and next-generation options. Subscription-style reimbursement could also affect patient churn and overall treatment persistence, especially where payers remain restrictive. For the industry, Novo’s decision signals a broader shift toward alternative commercial packaging beyond traditional pharmacy fill and insurance coverage—particularly as oral GLP-1 products gain traction.